Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charalabos-Markos Dintsios

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|May 17, 2021
A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?Charalabos-Markos Dintsios
International Journal of Technology Assessment in Health Care|February 20, 2018
INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANYCharalabos-Markos Dintsios, Sara Schlenkrich
Pharmacoeconomics|January 7, 2020
Determinants of Orphan Drug Prices in GermanyFranziska Worm, Charalabos-Markos Dintsios
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 27, 2018
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in GermanyMatthias Herpers, Charalabos-Markos Dintsios
Expert Review of Pharmacoeconomics & Outcomes Research|February 12, 2020
Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTAMarkus Molitor, Charalabos-Markos Dintsios
Health Policy (Amsterdam, Netherlands)|April 2, 2018
Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugsInes Niehaus, Charalabos-Markos Dintsios
GMS Health Technology Assessment|February 4, 2011
The impact of HTA reports on health policy: a systematic reviewAnsgar Gerhardus, Charalabos-Markos Dintsios
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' ExperienceSaskia Ludwig, Charalabos-Markos Dintsios
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|April 4, 2015
[Subgroups in the early benefit assessment of pharmaceuticals: a methodical review]Andrej Rasch, Charalabos-Markos Dintsios
Journal of Human Hypertension|March 24, 2026
How do patients with primary hypertension assess different endpoints of their treatment? a survey using analytic hierarchy processCharalabos-Markos Dintsios, Nadezda Chernyak
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Expert Review of Pharmacoeconomics & Outcomes Research|May 17, 2021
A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?Charalabos-Markos Dintsios
International Journal of Technology Assessment in Health Care|February 20, 2018
INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANYCharalabos-Markos Dintsios, Sara Schlenkrich
Pharmacoeconomics|January 7, 2020
Determinants of Orphan Drug Prices in GermanyFranziska Worm, Charalabos-Markos Dintsios
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 27, 2018
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in GermanyMatthias Herpers, Charalabos-Markos Dintsios
Expert Review of Pharmacoeconomics & Outcomes Research|February 12, 2020
Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTAMarkus Molitor, Charalabos-Markos Dintsios
Health Policy (Amsterdam, Netherlands)|April 2, 2018
Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugsInes Niehaus, Charalabos-Markos Dintsios
GMS Health Technology Assessment|February 4, 2011
The impact of HTA reports on health policy: a systematic reviewAnsgar Gerhardus, Charalabos-Markos Dintsios
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' ExperienceSaskia Ludwig, Charalabos-Markos Dintsios
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|April 4, 2015
[Subgroups in the early benefit assessment of pharmaceuticals: a methodical review]Andrej Rasch, Charalabos-Markos Dintsios
Journal of Human Hypertension|March 24, 2026
How do patients with primary hypertension assess different endpoints of their treatment? a survey using analytic hierarchy processCharalabos-Markos Dintsios, Nadezda Chernyak
Pageof 5